MAYNF (Mayne Pharma Group) Beginning Cash Position: $39.8 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MAYNF Mayne Pharma Group Ltd MAYNF
52 GF Score
Price $1.97
GF Value $3.70
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Mayne Pharma Group Beginning Cash Position?

Mayne Pharma Group MAYNF 52 Beginning Cash Position is $39.8 Mil as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 52/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review.

Mayne Pharma Group's Beginning Cash Position for the quarter that ended in Dec. 2025 was $39.8 Mil.

Mayne Pharma Group's quarterly Beginning Cash Position declined from Dec. 2024 ($69.7 Mil) to Jun. 2025 ($35.0 Mil) but then increased from Jun. 2025 ($35.0 Mil) to Dec. 2025 ($39.8 Mil).

Mayne Pharma Group's annual Beginning Cash Position declined from Jun. 2023 ($64.9 Mil) to Jun. 2024 ($61.5 Mil) but then increased from Jun. 2024 ($61.5 Mil) to Jun. 2025 ($71.7 Mil).

Mayne Pharma Group Beginning Cash Position Related Terms

Mayne Pharma Group Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Mayne Pharma Group's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mayne Pharma Group Beginning Cash Position Chart

Mayne Pharma Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 105.34 68.85 64.88 61.50 71.66

Mayne Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.99 72.53 69.71 34.97 39.76
MAYNF
52GF Score
Mayne Pharma Group Ltd MAYNF
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mayne Pharma Group Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $39.8 Mil mean?
Mayne Pharma Group (MAYNF) has a Beginning Cash Position of $39.8 Mil as of Dec. 2025. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Mayne Pharma Group and its competitors.
Is Mayne Pharma Group's Beginning Cash Position too high?
Mayne Pharma Group's current Beginning Cash Position is $39.8 Mil. Overall, Mayne Pharma Group has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Beginning Cash Position compare to MCK and CAH?
Mayne Pharma Group's Beginning Cash Position of $39.8 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Distribution company?
A good Beginning Cash Position depends on the Medical Distribution industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Mayne Pharma Group and its competitors. Mayne Pharma Group's current Beginning Cash Position is $39.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.97 — trading 46.7% below its estimated fair value. The current Beginning Cash Position is $39.8 Mil. Mayne Pharma Group's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Beginning Cash Position is $39.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mayne Pharma Group (MAYNF) Overvalued in 2026?

Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued. The current stock price of $1.97 is trading 46.7% below its estimated GF Value™ of $3.70. GuruFocus considers Mayne Pharma Group to be Possible Value Trap.

Key valuation signals for MAYNF:

  • Beginning Cash Position: $39.8 Mil
  • GF Value™: $3.70 vs. price of $1.97 (46.7% below fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mayne Pharma Group Business Description

Other Exchanges MYX:Australia
Address 1538 Main North Road, Salisbury South, Salisbury, SA, AUS, 5106
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
52GF Score

Get the complete analysis for MAYNF

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.97
Price
$3.70
GF Value